Jesus Avila | Tauopathies | Best Researcher Award

Posted on by Cognitive Scientist Awards

Prof. Jesus Avila | Tauopathies | Best Researcher Award

Dr. Jesus Avila is a distinguished cognitive scientist and Professor ad honorem at the Centro de Biologia Molecular Severo Ochoa (CBM-CSIC), Spain. He obtained his degree in Chemistry and PhD in Molecular Biology from Universidad Complutense Madrid, focusing on RNA polymerase in B. subtilis. His postdoctoral research at NIH, USA, centered on the SV40 virus. Throughout his prolific career, Dr. Avila has made groundbreaking contributions to understanding the neuronal cytoskeleton, particularly tau protein, its role in Alzheimer’s disease, and tauopathies. With over 694 published journal articles, 33 books, 4 patents, and collaborations across the USA, France, UK, Germany, and Spain, his work is internationally recognized. He serves on editorial boards of prestigious journals including EMBO J, FEBS Letters, Neuroscience, and Journal of Alzheimer’s Disease (Deputy Editor). Dr. Avila is a member of EMBO, Academia Europaea, AAAS, and Royal Academies of Sciences and Medicine of Spain.

Professional Profile

Education

Dr. Jesus Avila pursued his higher education at Universidad Complutense Madrid (UCM), earning a degree in Chemistry. He further specialized by completing a PhD in Molecular Biology at UCM, where his research focused on the B. subtilis RNA polymerase system. This solid foundation in molecular biology provided him with the expertise to investigate complex neurobiological mechanisms. He then advanced his academic career with postdoctoral training at the National Institutes of Health (NIH) in Bethesda, Maryland, USA, where he studied the SV40 virus—a crucial step that introduced him to advanced molecular virology and neurobiology techniques. This diverse academic background enabled him to establish a globally recognized research portfolio in neurodegeneration, particularly tau protein’s role in neuronal function and dysfunction.

Experience

Dr. Avila has an illustrious career spanning several decades at the Centro de Biologia Molecular Severo Ochoa (CBM-CSIC), where he has led pioneering research into the neuronal cytoskeleton, tau protein dysfunction, and neurodegenerative diseases. His early research at NIH on SV40 virus provided him with robust molecular expertise, which he translated into comprehensive studies on tauopathies and Alzheimer’s disease upon returning to Spain. Dr. Avila has successfully led over 30 major research projects, consulted on 8 industry collaborations, and published 694 peer-reviewed articles. His work includes the authorship of 33 books and the filing of 4 patents. Through sustained collaborations with global leaders in neuroscience from the USA, France, UK, Germany, and Spain, he has significantly advanced the understanding of aging and cognitive decline. His academic leadership and editorial roles underscore his vast experience in guiding both research and scientific discourse.

Research Interests

Dr. Avila’s research primarily investigates the neuronal cytoskeleton, with a central focus on tau protein and its role in neurodegeneration. Beginning with tau’s structural function in neurons, his work has expanded to explore how tau dysfunction contributes to Alzheimer’s disease and other tauopathies. Utilizing molecular and cellular approaches, including advanced mouse models, he has dissected the pathological mechanisms linking tau pathology to cognitive decline. Recognizing aging as the principal risk factor for Alzheimer’s disease, his current investigations target neuronal rejuvenation strategies to mitigate age-associated neurodegeneration. His integrative approach combines molecular biology, neurogenetics, and translational models, contributing significantly to the understanding of disease progression and potential therapeutic interventions. Through over 694 publications, 33 books, multiple patents, and international collaborations, Dr. Avila has substantially advanced the field of cognitive neuroscience, particularly in understanding and combating tau-mediated cognitive disorders.

Awards

Dr. Avila’s exemplary contributions have earned him numerous prestigious honors. He is an elected member of EMBO (European Molecular Biology Organization), Academia Europaea, AAAS (American Association for the Advancement of Science), and both the Royal Academies of Sciences and Medicine of Spain—testament to his global recognition and scientific excellence. His editorial appointments with highly respected journals such as EMBO J, FEBS Letters, Neuroscience, and his role as Deputy Editor of the Journal of Alzheimer’s Disease further validate his authority in cognitive and neurodegenerative research. His citation index surpasses 100 on Scopus, reflecting the significant influence of his work. His extensive collaborations with leading international research teams highlight his status as a respected leader in the global scientific community. The combination of his research excellence, mentorship, and leadership has positioned him as one of the foremost experts in cognitive science and neurobiology.

Conclusion

Dr. Jesus Avila’s distinguished career combines pioneering research on tau protein and Alzheimer’s disease, extensive international collaborations, over 694 publications, leadership roles in major journals, multiple prestigious memberships, and an unwavering focus on neuronal rejuvenation strategies, positioning him as a world-leading cognitive scientist whose work continues to advance global understanding of neurodegeneration.

 Publications

  • Protein tau phosphorylation in the proline rich region and its implication in the progression of Alzheimer’s disease

    Experimental Neurology
    2025 | Journal article
    DOI: 10.1016/j.expneurol.2024.115049

    EID:

    2-s2.0-85208758184

    Part ofISSN: 10902430 00144886
    CONTRIBUTORS: Merino-Serrais, P.; Soria, J.M.; Arrabal, C.A.; Ortigado-López, A.; Esparza, M.Á.G.; Muñoz, A.; Hernández, F.; Ávila, J.; DeFelipe, J.; León-Espinosa, G.

  • Retrotransposon Protein L1 ORF1p Expression in Aging Central Nervous System

    International Journal of Molecular Sciences
    2025-05-04 | Journal article
    DOI: 10.3390/ijms26094368
    CONTRIBUTORS: Laura Vallés-Saiz; Aaron Abdelkader-Guillén; Jesús Ávila; Félix Hernández

  • Shapeshifter W-Tau Peptide Inhibits Tau Aggregation and Disintegrates Paired Helical Filaments

    Biochemistry
    2025-04-15 | Journal article
    DOI: 10.1021/acs.biochem.4c00809
    CONTRIBUTORS: Indalo Domene-Serrano; Raquel Cuadros; Vega García-Escudero; Francisco Vallejo-Bedia; Ismael Santa-María; Laura Vallés-Saiz; Félix Hernandez; Jesús Avila

  • Peptide Family Promotes Brain Cell Rejuvenation and Improved Cognition through Peripheral Delivery

    ACS Omega
    2025-04-08 | Journal article
    DOI: 10.1021/acsomega.4c10849
    CONTRIBUTORS: Alejandro Anton-Fernandez; Indalo Domene-Serrano; Raquel Cuadros; Rocio Peinado-Cahuchola; Margarita Sanchez-Pece; Felix Hernandez; Jesus Avila

  • Partial reprogramming by cyclical overexpression of Yamanaka factors improves pathological phenotypes of tauopathy mouse model of human Alzheimer\’s disease

    Progress In Neurobiology
    2025-04-01 | Journal article | Author
    DOI: 10.1016/j.pneurobio.2025.102743

    SOURCE-WORK-ID:

    CSIC-GB950859

    EID:

    2-s2.0-85219079150

    Part ofISSN: 0301-0082
    CONTRIBUTORS: Alejandro Anton-Fernandez; Ruiz de Alegría, Álvaro; Mariscal-Casero, Ana; Roldán-Lázaro, Marta; Peinado-Cauchola, Rocío; Jesus Avila; Felix Hernandez

  • Hippocampal rejuvenation by a single intracerebral injection of one‐carbon metabolites in C57BL6 old wild‐type mice

    Aging Cell
    2025-01 | Journal article
    DOI: 10.1111/acel.14365
    CONTRIBUTORS: Alejandro Antón‐Fernández; Rocío Peinado Cauchola; Félix Hernández; Jesús Ávila

  • Intron retention as a productive mechanism in human MAPT: RNA species generated by retention of intron 3

    eBioMedicine
    2024 | Journal article
    DOI: 10.1016/j.ebiom.2023.104953

    EID:

    2-s2.0-85181837483

    Part ofISSN: 23523964
    CONTRIBUTORS: Ruiz-Gabarre, D.; Vallés-Saiz, L.; Carnero-Espejo, A.; Ferrer, I.; Hernández, F.; Garcia-Escudero, R.; Ávila, J.; García-Escudero, V.

  • Involvement of the cellular prion protein in seeding and spreading of sarkosyl-derived fractions of Alzheimer´s disease in Prnp mutant mice and in the P301S transgenic tauopathy mice model

    bioRxiv
    2024 | Other
    DOI: 10.1101/2024.01.20.576414

    EID:

    2-s2.0-85184321414

    Part of ISSN: 26928205
    CONTRIBUTORS: Sala-Jarque, J.; Gil, V.; Andrés-Benito, P.; Lidón, L.; Yanac-Huertas, R.E.; López-León, C.F.; Hernández, F.; Ávila, J.; Lanciego, J.L.; Soriano, J. et al.

Mai Osman Mohamed Kadry | Biochemistry | Best Researcher Award

Posted on by Cognitive Scientist Awards

Assist. Prof. Dr. Mai Osman Mohamed Kadry | Biochemistry | Best Researcher Award

Assist. Prof. Dr. Mai O.Kadry,National Research Center, Egypt

Dr. Mai Osman Mohamed Kadry is a distinguished biochemistry researcher at the Therapeutic Chemistry Department, National Research Centre, Egypt. With a Doctorate in Biochemistry from Cairo University (2016), her work focuses on oxidative injury, nanotoxicity, and cancer therapy. She has published extensively in high-impact journals on topics like antioxidant effects, stem cell therapies, and metabolic disorders. Dr. Kadry has also contributed to academia, teaching pharmacognosy at 6th October University. Skilled in advanced techniques like PCR, HPLC, and ELISA, she actively participates in groundbreaking nanobiotechnology research projects. Dr. Kadry is committed to advancing therapeutic strategies for critical diseases. 📚🧬

Profile

🎓 Education

Assist. Prof. Dr. Mai O. Kadry boasts a strong academic foundation in pharmaceutical sciences. She earned her Doctorate in Biochemistry from the Faculty of Pharmacy, Cairo University, in 2016, with a thesis on the “Amelioration of Nano-Sized Titanium Dioxide-Induced Oxidative Injury in Mice by Some Antioxidants.” She obtained her Master’s degree in Pharmaceutical Sciences from Helwan University in 2008, focusing on the synergistic effects of phytic and catechin on carbon tetrachloride-induced damage in rats. Dr. Kadry completed her B.Sc. in Pharmaceutical Science at Ain Shams University in 2003, graduating with honors. She also attended English language schools, enhancing her global communication skills. 🌟🔬

🧪 Experience

Assist. Prof. Dr. Mai O. Kadry has accumulated valuable experience in academia and research. She served as a pharmacognosy instructor at the Faculty of Pharmacy, 6th October University, Cairo, Egypt (2003–2004), where she effectively delivered courses on natural products and their therapeutic applications. Dr. Kadry also contributed as a staff member focused on development and quality enhancement, aligning with the standards of the National Commission for Academic Accreditation. Her dedication to education and quality assurance reflects her commitment to fostering academic excellence and professional growth in pharmaceutical sciences. 📚🔬

Training 🧬📚

Assist. Prof. Dr. Mai O. Kadry has undergone extensive training in various scientific disciplines. She completed courses in Biostatistics (November 2016) and Bioinformatics (January 2017) at the National Research Centre. Earlier, she gained expertise in Scientific Typewriting Bases (March 2007) and Occupational Health and Safety (June 2009). Additionally, she mastered Protein Electrophoresis through a four-month course in 2006. Dr. Kadry enhanced her practical skills with hands-on training at Al-Borg Clinical Laboratory, focusing on PCR techniques for detecting HBV and HCV at the Theodor Bilharz Research Institute. Her comprehensive training equips her with valuable laboratory and analytical skills. 🔬🧪

🔬 Research Focus

Assist. Prof. Dr. Mai O. Kadry focuses on cutting-edge biomedical research, emphasizing toxicity, cancer therapy, and molecular biology. Her work explores inflammatory mediators, DNA damage, and therapeutic approaches in liver, brain, and nephrotoxicity contexts. She investigates autophagy, necroptosis, and novel strategies like resveratrol nano-formulations for ovarian cancer. Dr. Kadry also studies molecular pathways in gastric and prostate cancers, including miRNA-lncRNA signaling and CRISPR-Cas9 applications. Other interests involve genetic mutations in leukemia, drug-delivery systems, and nanotechnology for breast cancer. Her contributions bridge diagnostics, therapeutic innovations, and cellular mechanisms in oncology and toxicology. 🔬✨

✅ Conclusion

Assist. Prof. Dr. Mai O. Kadry is a distinguished biochemistry researcher whose work bridges advanced molecular biology and therapeutic innovation. With expertise in nanotoxicity, oxidative injury, and cancer therapy, she contributes significantly to biomedical science through impactful research and academic leadership. Her training in cutting-edge techniques and her focus on translational medicine position her at the forefront of scientific discovery. Dr. Kadry’s dedication to improving healthcare through targeted therapies and her commitment to academic excellence make her a valuable asset to the scientific community. Her career reflects passion, innovation, and a relentless pursuit of better treatment solutions.

 

Publications

  • Collaboration of Hprt/K-RAS/c-Myc mutation in the oncogenesis of T-lymphocytic leukemia: a comparative study

    Future Science OA
    2024-12-31 | Journal article
    DOI: 10.2144/fsoa-2023-0111
    CONTRIBUTORS: Mai O Kadry; Abdel-Hamid Z Abdel Hamid; Rehab M Abdel-Megeed

  • Fischer’s oligopeptide ratio in ischemic hypoxia: prophylactic amendment of sophoretin and melatonin supplementation

    Future Science OA
    2024-12-31 | Journal article
    DOI: 10.2144/fsoa-2023-0117
    CONTRIBUTORS: Mai O Kadry; Hanaa Mahmoud Al

  • Thioctic acid shield against lipopolysaccharide depression and endoplasmic reticulum stress: GR7M/Homer/ATF6 signaling

    Future Science OA
    2024-12-31 | Journal article
    DOI: 10.1080/20565623.2024.2422791
    CONTRIBUTORS: Mai O. Kadry; Rehab M. Abdel-Megee

Yingna Le | Research on the Mechanism of Action of Active Ingredients in Traditional Chinese Medicine | Best Researcher Award

Posted on by Cognitive Scientist Awards

Dr. Yingna Le | Research on the Mechanism of Action of Active Ingredients in Traditional Chinese Medicine | Best Researcher Award

PhD Candidate| Nanchang Medical College, china

Dr. Yingna Le is a Lecturer in Pharmacy at Nanchang Medical College’s School of Pharmacy, where she specializes in pharmacognosy and the authentication of Chinese medicinal materials. With a strong foundation in Chinese Materia Medica from Yunnan and Jiangxi Universities of Traditional Chinese Medicine, she combines traditional knowledge with modern scientific research. Dr. Le actively investigates the molecular mechanisms behind active ingredients in Traditional Chinese Medicine (TCM), contributing to national and provincial research projects. Her work includes the study of hawthorn leaf flavonoids and kidney stone treatments through the lens of network pharmacology and gut-liver axis analysis. She has published in core Chinese and international journals, developed flipped classroom models, and innovated WeChat-based educational tools. A member of several professional societies, she is committed to advancing TCM education and research. Her interdisciplinary approach integrates experimental design, pharmacognosy, and data analysis to enrich teaching and contribute to the scientific community.

Profile

🎓 Education

Dr. Yingna Le holds both Bachelor’s and Master’s degrees in Chinese Materia Medica. She earned her B.S. from Yunnan University of Traditional Chinese Medicine in 2007, where she developed a strong understanding of traditional pharmacognosy and the foundational principles of Chinese medicine. She then pursued her M.S. from Jiangxi University of Traditional Chinese Medicine (2008–2011), deepening her expertise in medicinal material authentication and TCM pharmacology. Her postgraduate studies provided her with skills in microscopic identification, phytochemical analysis, and TCM theory, setting the stage for her research and teaching career. This rigorous academic background enabled her to bridge the gap between traditional practices and contemporary scientific methods. Her educational journey laid the groundwork for her future roles in academia and research, where she continues to explore the integration of modern pharmacological techniques with ancient herbal wisdom. Dr. Le’s academic path demonstrates her dedication to excellence and innovation in the field of TCM.

🧪 Experience

Dr. Yingna Le currently serves as a Lecturer in the School of Pharmacy at Nanchang Medical College (2021–present), where she teaches Pharmacognosy and the Authentication of Chinese Medicinal Materials. Prior to this, she was a Teaching Assistant at the Jiangxi University of TCM Science and Technology College (2018–2021), where she began integrating innovative teaching strategies into traditional Chinese medicine education. Her academic career is marked by a dedication to improving teaching quality through flipped classrooms and the application of digital platforms like WeChat for student engagement and evaluation. In addition to teaching, Dr. Le has played pivotal roles in research, particularly as Principal Investigator and Co-Investigator on national and provincial research grants. She has completed five interdisciplinary projects between 2020 and 2022 and actively contributes to academic publications. Her blend of instructional innovation and research acumen makes her a respected figure in both educational and scientific circles in TCM.

🏅 Awards and Honors

Dr. Yingna Le has earned recognition through competitive research funding and influential academic appointments. She is the Principal Investigator of a Jiangxi Provincial Education Department grant for studying Lygodium japonicum’s mechanisms against kidney stones, and a Co-Investigator on a prestigious National Natural Science Foundation of China (NSFC) grant examining hawthorn leaf flavonoids in cardiovascular treatment. While specific award titles are not listed, her success in securing these high-level grants reflects her scientific credibility and innovation. Additionally, her involvement in five interdisciplinary education reform and material science projects (2020–2022) with substantial budgets highlights her leadership and collaborative spirit. Dr. Le also holds committee roles in key professional societies, including the TCM Processing Committee of the Jiangxi Pharmaceutical Association and the Digital Healthcare & Simulation Medicine Society of Jiangxi Province. These roles further affirm her status as a trusted contributor to the advancement of pharmacy education and research in Traditional Chinese Medicine.

🔬 Research Focus

Dr. Yingna Le’s research centers on uncovering the mechanisms of action of active ingredients in Traditional Chinese Medicine using modern pharmacological approaches. Her work focuses on compounds such as hawthorn leaf flavonoids and their effects on cardiovascular health, particularly unstable plaques, through the LXR-α mediated modulation of iron-lipid metabolism in the gut-liver axis. She also investigates the therapeutic potential of Lygodium japonicum in kidney stone treatment via network pharmacology. Dr. Le employs a range of methodologies including phytochemical analysis, molecular mechanism studies, and pharmacognostic techniques. Her research approach integrates traditional herbal knowledge with systems biology to bridge classical TCM theory with modern biomedical science. She has a strong interest in interdisciplinary collaboration and has led or contributed to numerous research projects across pharmacology, education reform, and material science. Her contributions aim to validate and modernize the application of traditional remedies in contemporary clinical settings, making her work both culturally relevant and scientifically impactful.

✅ Conclusion

Dr. Yingna Le blends traditional Chinese medical expertise with modern research to advance pharmacognosy and medicinal authentication. Through dedicated teaching, impactful research, and innovative education methods, she contributes significantly to TCM modernization.

Publications

Carmela Conte | Neurodegenerative diseases | Best Researcher Award

Posted on by Cognitive Scientist Awards

Prof Dr. Carmela Conte | Neurodegenerative diseases | Best Researcher Award

 

Profile

Education

Carmela Conte obtained her Master’s degree in Biological Sciences from the University of Perugia on November 3, 1994. She then pursued a Ph.D. in Medical Embryology through a joint program between the Universities of Perugia and Ferrara, completing it between December 30, 1996, and January 19, 2000. Following this, she specialized in Chemistry and Food Technology at the University of Perugia, earning her specialization between November 1, 2000, and November 1, 2002. Most recently, on September 29, 2023, she received National Habilitation as an Associate Professor in Biochemistry. She currently serves as an Aggregate Professor in her field.

Work experience

Since September 7, 2007, Carmela Conte has been serving as an Aggregate Professor in Biochemistry at the University of Perugia, where she teaches courses in General and Systematic Biochemistry, Medical Applied Biochemistry, and Molecular Biology. In addition to her teaching responsibilities, she participated in a Teaching and Training Mobility Program at VUMC Medical University of Amsterdam from June 24 to July 5, 2019, where she worked on a research project investigating the role of Toll-like receptors in Parkinson’s disease. She has been a member of the European Society for Neurochemistry since 2007 and, since March 17, 2022, has also been affiliated with the International Parkinson and Movement Disorder Society.

Research Activity

Carmela Conte’s research focuses on neurodegenerative diseases, with particular emphasis on animal models, signal transduction, molecular biology, and cell biology. Her specific research topics include the role of Toll-like receptors in Parkinson’s disease, neuroinflammation, synucleinopathies, oxidative stress, and Parkinson’s disease. Since September 7, 2007, she has been actively involved in editorial work, serving as a Reviewer Editor for Frontiers in Neuroscience (Neurodegeneration section) and as an ad hoc reviewer for several journals, including Amino Acids, The Cerebellum, Free Radical Research, Biomolecules, PLOS One, Experimental Gerontology, Molecules, Cells, Neurochemical Research, Neuroscience, Pharmacological Reports, International Journal of Molecular Sciences, Viruses, and the Journal of Biotechnology. Additionally, she has been a Guest Editor for Molecules and Cells, overseeing special issues and topic collections on neurodegenerative diseases. She has presented her research at numerous scientific meetings and conferences, including the 2009 Meeting of the European Society for Neurochemistry in Leipzig, the 2019 European Biotechnology Congress in Valencia, the 2021 European Biotechnology Congress in Sofia, the 2022 National Meeting of the Sphingolipid Club, and the 2023 Meeting of Parkinson’s Disease and Movement Disorders, where she discussed findings related to Toll-like receptor 4, alpha-synuclein accumulation, and sphingomyelinase activity in Parkinson’s disease models.

Publication